CAMBRIDGE, England. Capsugel, the leading global provider of dosage form solutions, announced today that its CFS1000/1200 capsule filling and sealing machines have now been licensed by eight of the top 10 global pharmaceutical companies. An integral part of the Licaps(R) Drug Delivery System, these companies are using the CFS1000/1200 capsule filling and sealing machines in early stage development and manufacturing of Phase 1 clinical trial materials.
Both the CFS1000 and CFS1200 models eliminate the need for banding capsules, while providing a secure and impervious capsule seal. By filling and sealing in one operation, it helps accelerate the development timeframe and achieve faster time to "First in Man" - the critical Phase 1 go/no go decision point for new molecules within the pharmaceutical development process.
Capsugel's Director of Pharmaceutical Technology, David Edwards said there is a reason for the increased customer interest: ''We see a growing number of poorly soluble molecules coming through R&D pipelines. The new CFS1200 facilitates rapid and scaleable development, thereby cutting R&D timescales and getting drugs into clinical trials as soon as possible. What we are finding now is that the CFS1200 is proving so invaluable that many companies are looking to purchase additional machines in order to capitalize on this unique technology."
In addition, a number of leading Contract Research Organisations (CROs), both in the United States and the European Union, have acquired CFS1000/1200 machines. These are being used to service pharmaceutical companies that wish to evaluate the Licaps drug delivery technology, as well as to provide additional capacity to those companies who already have the CFS1000/1200 equipment in place.
The CFS1200 will be on display on the Capsugel stand at the AAPS Annual Meeting in San Diego, Calif., USA, November 11-15th 2007.
The CFS1200 is also available for demonstrations at Capsugel's sites in Illkirch, France; Bornem, Belgium; Greenwood, S.C., USA; and Sagamihara, Japan.